FIELD-LAB is a drug discovery facility that will help you to speed up the development and market launch of new nuclear drugs for cancer treatment. Through supply of small batches of radio chemicals and radio pharmaceuticals, we meet the need of Bio Pharma scientists and start-up ventures for research materials. This will drive both their ambitions to develop a new drug.
FIELD-LAB is part of a unique and complete nuclear infrastructure.
Read more about Nuclear Infrastructure
Currently, research is done on the production and development of various isotopes:
Learn more about FIELD-LAB and its importance. Discover our global network for pre-clinical and clinical research: research that is part of the development of every new medical product.
FIELD-LAB is created for and together with partners from different backgrounds. Some of the finest Dutch UMC’s have committed themselves to be part of this initiative. They believe in the beneficial results that will be brought to the Nuclear Medicine society. In addition, the partnerships that arise from FIELD-LAB form a portal to a fast growing network, which results in an open innovation environment.
During the NVNG Spring Conference of last Friday our R&D manager Karlijn van der Schilden provided insight into the current developments of NRGǀPALLAS in the field of developing new production routes for existing and new isotopes. With inextricably linked the subject of securing availability and supply.
In the University of Warwick and King’s College London, the FIELD-LAB of NRG has found its first international partners. Despite the significant barriers created by both the COVID-pandemic and Brexit, researchers and scientists on both sides of the Channel managed to get things started and hope to present exciting new findings in due time. Dr Cinzia Imberti, Sir Henry Wellcome Postdoctoral Fellow, University of Warwick, UK and Nora Klaassen, project manager R&D at Field-Lab, Petten, the Netherlands, shed some light on how this collaboration started and its hopes for the future.